Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation

[1]  M. Shipp,et al.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Savage,et al.  Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study , 2016, The Lancet. Oncology.

[3]  F. Hodi,et al.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.

[4]  J. McGuirk,et al.  Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma , 2016, Bone Marrow Transplantation.

[5]  L. Stegger,et al.  Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation , 2016, Bone Marrow Transplantation.

[6]  Rushang D. Patel,et al.  Steroid Refractory Acute Liver GVHD in a Hodgkin's Patient after Allogeneic Stem Transplant Cell Transplantation Following Treatment with Anti PD-1 Antibody, Nivolumab, for Relapsed Disease , 2016 .

[7]  S. Ansell,et al.  Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective , 2016, Oncotarget.

[8]  R. Houot,et al.  Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC , 2015 .

[9]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[10]  D. Munn,et al.  Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. , 2013, Blood.

[11]  Michael R. Green,et al.  Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy , 2012, Clinical Cancer Research.

[12]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[13]  R. Yamamoto,et al.  PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. , 2007, Blood.

[14]  N. Geller,et al.  Improved survival in steroid‐refractory acute graft versus host disease after non‐myeloablative allogeneic transplantation using a daclizumab‐based strategy with comprehensive infection prophylaxis , 2004, British journal of haematology.